Ontology highlight
ABSTRACT:
SUBMITTER: Zhu Y
PROVIDER: S-EPMC6086110 | biostudies-literature | 2018
REPOSITORIES: biostudies-literature
Cancer management and research 20180807
Immune checkpoint inhibitors (ICIs), represented by anti-CTLA-4 or anti-PD-1/anti-PD-L1 pathway antibodies, have led to a revolution in cancer treatment modalities. ICIs have unique clinical benefits, such as effectiveness against a broad range of tumor types, strong overall impact on survival, and persistent responses after the cessation of therapy. However, only a subset of patients responds to these therapies, and a small proportion of patients even experience rapid progression or an increase ...[more]